Fermion Technology and Simcere Pharma Join Hands to Develop FZ002-037 for Pain Management
Shots:
- Fermion & Simcere Pharma have entered into an exclusive license and collaboration agreement to develop FZ002-037 for pain management
- As per the agreement, Simcere secures exclusive rights to develop & commercialize FZ002-037 across Greater China (Mainland China, Hong Kong, Macau & Taiwan) in exchange for an undisclosed upfront, milestones and sales-based tiered royalties
- Fermion’s FZ002-037 (oral) is a highly selective SSTR4 targeting small molecule that has depicted peripheral analgesia without central side effects or addiction risks plus has concluded P-I Chinese study. P-II trial for diabetic peripheral neuropathy will start soon, with its expansion to various chronic & acute pain conditions
Ref: Prnewswire | Image: Fermion & Simcere
Related News:- Simcere Zaiming and TargetRx Team Up to Develop TGRX-326 for Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha was a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
